Microsoft is delving even deeper into clinical medicine, evident by the announcement today highlighting the company’s development of a foundation model for pathology in partnership with Providence and ...

Precision medicine is reshaping the landscape of clinical development, offering more advanced strategies to align therapies with individual biological variability. Recent research shows that drug ...

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program ...

TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.

David Figge, M.D., Ph.D., joins the Department of Pathology’s Division of Laboratory Medicine, led by Sixto Leal, M.D., Ph.D., as an assistant professor and Director of Clinical Immunology effective ...

The National Institutes of Health has spent most of its nearly $1.7 billion in funding for long COVID on research designed to learn more about the condition rather than on trials for new treatments—a ...

Bio-Path Holdings, Inc. has provided an update on its clinical developments during a recent conference call. The company is focused on using its DNAbilize® liposomal delivery technology to develop ...

Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...

Lyme disease is the most commonly reported vector-borne disease in the United States. While most cases are effectively treated through oral antibiotics, some patients develop persistent and ...

Huxley Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial release of central sleep apnea (CSA) detection for its SANSA(R) home sleep apnea test.